-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $53

Benzinga·02/25/2026 14:54:45
Listen to the news
Wells Fargo analyst Eva Fortea Verdejo maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Overweight and raises the price target from $50 to $53.